Login to Your Account


At ASCO '11, Targeting Successes Spur Next-Generation Approaches

By Anette Breindl

Monday, June 6, 2011
CHICAGO – The 47th annual meeting of the American Society for Clinical Oncology began with something of an ode to targeted therapy. In data presented in a session on personalized medicine, researchers from the University of Texas MD Anderson Cancer Center showed that when end-stage cancer patients had their tumors analyzed and received targeted therapies that matched their mutations, the response rate more than quintupled and survival increased by several months.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription